Meghana Keshavan covers biotech and contributes to The Readout newsletter. It’s been a hard week for the psychedelics pioneer Rick Doblin. First, the Food and Drug Administration declined to approve ...
Rick Doblin spent more than 30 years trying to turn the psychedelic drug MDMA into an accepted medical treatment for post-traumatic stress disorder. Earlier this month, the Food and Drug ...
Rick Doblin, Ph.D., founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS) at PS2023. Psychedelic Science 2025 (PS2025) is inviting trauma therapists and other ...
MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for ...
Reason's Nick Gillespie talked with MAPS founder Rick Doblin about the imminent FDA approval of MDMA- and psilocybin-assisted therapy at the Psychedelic Science conference in Denver.
Editor's Note: A version of this post was first published in WBUR's weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox, sign up here. This post has been ...
Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical" or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results